 |
PDBsum entry 1vm1
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
40:1861-1866
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam.
|
|
A.P.Kuzin,
M.Nukaga,
Y.Nukaga,
A.Hujer,
R.A.Bonomo,
J.R.Knox.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Two species resulting from the reaction of the SHV-1 class A beta-lactamase with
the sulfone inhibitor tazobactam have been trapped at 100 K and mapped by X-ray
crystallography at 2.0 A resolution. An acyclic form of tazobactam is covalently
bonded to the catalytic Ser70 side chain, and a second species, a five-atom
vinyl carboxylic acid fragment of tazobactam, is bonded to Ser130. It is
proposed that the electron density map of the crystal is a composite picture of
two complexes, each with only a single bound species. It is estimated that the
two complexes exist in the crystal in approximately equal populations. Results
are discussed in relation to the mechanism-based inhibition of class A
beta-lactamases by the similar inhibitors sulbactam and clavulanic acid.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.F.Kluge,
and
R.C.Petter
(2010).
Acylating drugs: redesigning natural covalent inhibitors.
|
| |
Curr Opin Chem Biol,
14,
421-427.
|
 |
|
|
|
|
 |
S.M.Drawz,
and
R.A.Bonomo
(2010).
Three decades of beta-lactamase inhibitors.
|
| |
Clin Microbiol Rev,
23,
160-201.
|
 |
|
|
|
|
 |
E.Sauvage,
A.Zervosen,
G.Dive,
R.Herman,
A.Amoroso,
B.Joris,
E.Fonzé,
R.F.Pratt,
A.Luxen,
P.Charlier,
and
F.Kerff
(2009).
Structural basis of the inhibition of class A beta-lactamases and penicillin-binding proteins by 6-beta-iodopenicillanate.
|
| |
J Am Chem Soc,
131,
15262-15269.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Kalp,
M.A.Totir,
J.D.Buynak,
and
P.R.Carey
(2009).
Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
|
| |
J Am Chem Soc,
131,
2338-2347.
|
 |
|
|
|
|
 |
P.Pattanaik,
C.R.Bethel,
A.M.Hujer,
K.M.Hujer,
A.M.Distler,
M.Taracila,
V.E.Anderson,
T.R.Fritsche,
R.N.Jones,
S.R.Pagadala,
F.van den Akker,
J.D.Buynak,
and
R.A.Bonomo
(2009).
Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.
|
| |
J Biol Chem,
284,
945-953.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.R.Bethel,
A.M.Distler,
M.W.Ruszczycky,
M.P.Carey,
P.R.Carey,
A.M.Hujer,
M.Taracila,
M.S.Helfand,
J.M.Thomson,
M.Kalp,
V.E.Anderson,
D.A.Leonard,
K.M.Hujer,
T.Abe,
A.M.Venkatesan,
T.S.Mansour,
and
R.A.Bonomo
(2008).
Inhibition of OXA-1 beta-lactamase by penems.
|
| |
Antimicrob Agents Chemother,
52,
3135-3143.
|
 |
|
|
|
|
 |
J.Mulchande,
L.Martins,
R.Moreira,
M.Archer,
T.F.Oliveira,
and
J.Iley
(2007).
The efficiency of C-4 substituents in activating the beta-lactam scaffold towards serine proteases and hydroxide ion.
|
| |
Org Biomol Chem,
5,
2617-2626.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.A.Totir,
M.S.Helfand,
M.P.Carey,
A.Sheri,
J.D.Buynak,
R.A.Bonomo,
and
P.R.Carey
(2007).
Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
|
| |
Biochemistry,
46,
8980-8987.
|
 |
|
|
|
|
 |
Y.Ishii,
M.Galleni,
L.Ma,
J.M.Frère,
and
K.Yamaguchi
(2007).
Biochemical characterisation of the CTX-M-14 beta-lactamase.
|
| |
Int J Antimicrob Agents,
29,
159-164.
|
 |
|
|
|
|
 |
F.Wang,
C.Cassidy,
and
J.C.Sacchettini
(2006).
Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.
|
| |
Antimicrob Agents Chemother,
50,
2762-2771.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.A.Totir,
P.S.Padayatti,
M.S.Helfand,
M.P.Carey,
R.A.Bonomo,
P.R.Carey,
and
F.van den Akker
(2006).
Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
|
| |
Biochemistry,
45,
11895-11904.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.S.Padayatti,
A.Sheri,
M.A.Totir,
M.S.Helfand,
M.P.Carey,
V.E.Anderson,
P.R.Carey,
C.R.Bethel,
R.A.Bonomo,
J.D.Buynak,
and
F.van den Akker
(2006).
Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.
|
| |
J Am Chem Soc,
128,
13235-13242.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Sulton,
D.Pagan-Rodriguez,
X.Zhou,
Y.Liu,
A.M.Hujer,
C.R.Bethel,
M.S.Helfand,
J.M.Thomson,
V.E.Anderson,
J.D.Buynak,
L.M.Ng,
and
R.A.Bonomo
(2005).
Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
|
| |
J Biol Chem,
280,
35528-35536.
|
 |
|
|
|
|
 |
L.Ma,
J.Alba,
F.Y.Chang,
M.Ishiguro,
K.Yamaguchi,
L.K.Siu,
and
Y.Ishii
(2005).
Novel SHV-derived extended-spectrum beta-lactamase, SHV-57, that confers resistance to ceftazidime but not cefazolin.
|
| |
Antimicrob Agents Chemother,
49,
600-605.
|
 |
|
|
|
|
 |
P.S.Padayatti,
M.S.Helfand,
M.A.Totir,
M.P.Carey,
P.R.Carey,
R.A.Bonomo,
and
F.van den Akker
(2005).
High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
|
| |
J Biol Chem,
280,
34900-34907.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
V.L.Thomas,
D.Golemi-Kotra,
C.Kim,
S.B.Vakulenko,
S.Mobashery,
and
B.K.Shoichet
(2005).
Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.
|
| |
Biochemistry,
44,
9330-9338.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Pagan-Rodriguez,
X.Zhou,
R.Simmons,
C.R.Bethel,
A.M.Hujer,
M.S.Helfand,
Z.Jin,
B.Guo,
V.E.Anderson,
L.M.Ng,
and
R.A.Bonomo
(2004).
Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
|
| |
J Biol Chem,
279,
19494-19501.
|
 |
|
|
|
|
 |
W.J.Weiss,
P.J.Petersen,
T.M.Murphy,
L.Tardio,
Y.Yang,
P.A.Bradford,
A.M.Venkatesan,
T.Abe,
T.Isoda,
A.Mihira,
H.Ushirogochi,
T.Takasake,
S.Projan,
J.O'Connell,
and
T.S.Mansour
(2004).
In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.
|
| |
Antimicrob Agents Chemother,
48,
4589-4596.
|
 |
|
|
|
|
 |
Y.Bourne,
H.C.Kolb,
Z.Radić,
K.B.Sharpless,
P.Taylor,
and
P.Marchot
(2004).
Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation.
|
| |
Proc Natl Acad Sci U S A,
101,
1449-1454.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.S.Helfand,
C.R.Bethel,
A.M.Hujer,
K.M.Hujer,
V.E.Anderson,
and
R.A.Bonomo
(2003).
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
|
| |
J Biol Chem,
278,
52724-52729.
|
 |
|
|
|
|
 |
M.S.Helfand,
M.A.Totir,
M.P.Carey,
A.M.Hujer,
R.A.Bonomo,
and
P.R.Carey
(2003).
Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
|
| |
Biochemistry,
42,
13386-13392.
|
 |
|
|
|
|
 |
M.S.Helfand,
A.M.Hujer,
F.D.Sönnichsen,
and
R.A.Bonomo
(2002).
Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase.
|
| |
J Biol Chem,
277,
47719-47723.
|
 |
|
|
|
|
 |
X.Wang,
G.Minasov,
and
B.K.Shoichet
(2002).
The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34.
|
| |
J Biol Chem,
277,
32149-32156.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.A.Powers,
E.Caselli,
P.J.Focia,
F.Prati,
and
B.K.Shoichet
(2001).
Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.
|
| |
Biochemistry,
40,
9207-9214.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |